Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Age-related Macular Degeneration, Diabetic Vascular Diseases, Proliferative Retinopathy, Retina Vein Occlusion
Interventions
Chlorhexidine, Povidine-Iodine
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy, Retinoschisis
Interventions
Triamcinolone, Bupivicaine Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Diabetic Retinopathy
Interventions
Vitreosolve
Drug
Lead sponsor
Vitreoretinal Technologies, Inc.
Industry
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Santa Ana, California + 7 more
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
OTX-TKI, Sham
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Bakersfield, California • Augusta, Georgia + 7 more
Conditions
Vitreous Detachment, Diabetic Retinopathy
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Beverly Hills, California • New York, New York • McAllen, Texas + 1 more
Conditions
Diabetic Retinopathy
Interventions
Photography of the retina, Retinal photography
Procedure
Lead sponsor
Digital Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Mesa, Arizona • Phoenix, Arizona • Cedar Rapids, Iowa + 2 more
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Completed Phase 2 Interventional Accepts healthy volunteers

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

NCT01769183
Conditions
Retinal Neovascularization
Interventions
Squalamine Lactate ophthalmic solution 0.2%
Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Completed No phase listed Observational

Diabetes PRP and OCT

NCT01928550
Conditions
Proliferative Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Retinopathy, Diabetic
Interventions
Aflibercept Injection, Sham injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Completed Not applicable Interventional Results available

Avastin for PDR (Proliferative Diabetic Retinopathy)

NCT01270542
Conditions
Retinal Detachment, Diabetic Retinopathy
Interventions
Avastin (bevacizumab), Sham injection
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Proliferative Diabetic Retinopathy
Interventions
Brolucizumab 6 mg, Panretinal photocoagulation laser
Biological · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
40
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
Conditions
Retinal Detachment, Vitreoretinopathy Proliferative
Interventions
Bevacizumab
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lynbrook, New York
Conditions
Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
Interventions
Ranibizumab, No Ranibizumab
Drug · Other
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Proliferative Diabetic Retinopathy
Interventions
Panretinal Photocoagulation, Lucentis
Device · Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions
OPL-0401 Dose 1, Placebo
Drug
Lead sponsor
Valo Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Mountain View, California • Riverside, California • Sacramento, California + 20 more
Conditions
Moderate Non-proliferative Diabetic Retinopathy
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
Ferris State University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Big Rapids, Michigan • Grand Rapids, Michigan
Conditions
Diabetic Retinopathy
Interventions
Runcaciguat (BAY1101042), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

NCT02976012
Conditions
Proliferative Diabetic Retinopathy
Interventions
Aflibercept, Endolaserless Vitrectomy
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Augusta, Georgia